MHRAsafety guidance54% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Eli Lilly.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Obesity · GLP-1 Agonists
- Sub-indication
- General
Related signal: Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program